DR. STEVEN H SELMAN, M.D.
Urology at Arlington Ave, Toledo, OH

6025351, Feb 15, 2000

Nov 26, 1997

8/979643

Alan R. Morgan - Las Vegas NV
Steven H. Selman - Toledo OH

University of Toledo - Toledo OH
Medical College of Ohio - Toledo OH

A61K 3166, A61K 3900, C07D48722

514185

Families of Diels Alder adducts and of metal complexes of Diels Alder adducts, which are useful as particularly active compounds for use in photodynamic therapy, are disclosed. The Diels Alder adducts and a preferred family of metal complexes have the structures of Formulas 3 and 4, below: ##STR1## where R1, R2, R3 and R4 can be the same or different, and each is methyl, ethyl, an amino acid moiety which is a part of an amide produced by reaction between an amine function of a naturally occurring amino acid and a carbonyl function of the adduct, or a monoclonal antibody moiety which is attached to the adduct moiety through a carbonyl which is a part of an amide produced by reaction between an amine function of a monoclonal antibody and a CO. sub. 2 R', CH. sub. 2 CO. sub. 2 R' or CH. sub. 2 CH. sub. 2 CO. sub. 2 R'group of the adduct, and wherein the moiety is of a monoclonal antibody which selectively binds to malignant tumors, R5, R6 and R7 can be the same or different, and each is ethyl, an amino acid moiety which is a part of an amide produced by reaction between an amine function of a naturally occurring amino acid and a carbonyl function of the adduct, or a monoclonal antibody moiety which is attached to the adduct moiety through a carbonyl which is a part of an amide produced by reaction between an amine function of a monoclonal antibody and a CO. sub. 2 R', CH. sub. 2 CO. sub.

5051415, Sep 24, 1991

Aug 2, 1989

7/388643

Alan R. Morgan - Toledo OH
Steven H. Selman - Toledo OH

The University of Toledo - Toledo OH
Medical College of Ohio - Toledo OH
St. Vincent Medical Center - Toledo OH

A61K 3140, C07D48722

514185

Families of chlorins, families of purpurins and metal complexes thereof are disclosed. The purpurins and their metal complexes have the structures of FIGS. 1, 7, 14-18, 29-38, 44-48 and 54-58 of the attached drawings. The chlorins and their metal complexes have the formulas of FIGS. 2, 8, 19, 20, 22, 23, 24, 25, 27, 28, 39, 40, 42, 43 and 49-53 of the attached drawings. Solutions of the purpurins, of the foregoing and other chlorins and of the metal complexes which are physiologically acceptable for intravenous administration are also disclosed, as are emulsions or suspensions of the solutions. The solvent for the solutions can be a product of the reaction of ethylene oxide with castor oil. A method for detecting and treating tumors in human and animal patients is also disclosed. The method comprises administering one of the purpurins, chlorins or metal complexes to the patient.

2010013, Jun 3, 2010

Sep 18, 2009

12/562750

Rafal Swiercz - Bastrop TX, US
Steven H. Selman - Toledo OH, US
Jerzy Jankun - Sylvania OH, US
Joanna Chorostowska-Wynimko - Warsaw, PL

A61K 38/16, C07K 14/00, A61P 9/10, A61P 7/04

514 12, 530350

The present invention is based upon the discovery that modified plasminogen activator inhibitor type-I (PAI-1) in which two or more amino acid residues that do not contain a sulfhydryl group have been replaced with amino acid residues that contain a sulfhydryl group and, therefore, forms intramolecular disulfide bonds, have increased in vivo half-life. Also disclosed are the modified PAI-1 proteins, derivatives and analogs thereof, specific antibodies, nucleic acid molecules and host cells. Methods for producing modified PAI-1, derivatives and analogs are also provided. The invention further relates to Therapeutics, pharmaceutical compositions and method of using the composition for treatment. The invention may be used to inhibit angiogenesis in a subject, thereby treating diseases or conditions associated with undesired angiogenesis and cell proliferation. Such conditions include psoriasis, chronic inflammation, tumor invasion and metastasis and conditions in which angiogenesis is pathogenic. The modified PAI-1 molecules of the present invention are useful for the treatment, prophylaxis, management and amelioration of cardiovascular diseases such as, but not limited to those that are related to hyperfibrinolysis, hemophilia, and vessel leakage syndrome.

6011563, Jan 4, 2000

Apr 24, 1995

8/427668

Ronald L. Fournier - Sylvania OH
Jeffrey Henning - Sylvania OH
James A. Hampton - Waterville OH
Steven H. Selman - Toledo OH

The University of Toledo - Toledo OH

G06F 9455, A61B 100, A61B 1736

345500

A system and method is provided for optimizing a laser light fractionation during photodynamic therapy of a tumor. The tumor is destroyed through the production of singlet oxygen and successful photodynamic therapy treatment requires the maintenance of tumor oxygen above a specified critical level. Depending on the tumor, the photosensitizer concentration, and the laser fluence, sustained irradiation of the tumor will deplete the oxygen below the critical level. When the laser is turned off, oxygen diffuses into the tumor to provide sustained levels of singlet oxygen. The control system controls the operation cycle of the laser and the various surgical parameters. Data regarding the sensitizer, the laser characteristics, and the oxygen features of the tumor are input into the control system for simulation of the PDT treatment. As part of the simulation, the optimal fractionation cycle for the laser is predicted. The data may be adjusted for conducting additional simulations.

5424305, Jun 13, 1995

Nov 24, 1993

8/158020

Dimitris Skalkos - Toledo OH
Steven H. Selman - Toledo OH
James A. Hampton - Waterville OH

The University of Toledo - Toledo
Medical College of Ohio - Toledo

A61K 3140, C07D48722

514185

Purified imines of porphyrins, chlorins, bateriochlorins, chlorophylls, bacteriochlorophylls, purpurins, reduced purpurins, verdins, Diels Alder adducts, benzochlorins and metal complexes of the foregoing imines are disclosed for retarding growth of cancer tumors such as bladder tumors. The formulas of the benzochlorinimines and of the benzochlorinimine metal complexes are set forth below: ##STR1## In specific examples, M in the metal complexes is a copper cation that is complexed with two of the nitrogens of the benzochlorinimine R' and R"" are methyl, and R1 through R8 are ethyl.

5250668, Oct 5, 1993

Jan 8, 1992

7/818133

Alan R. Morgan - Swanton OH
Steven H. Selman - Toledo OH

C07F 108, C07F 306, C07F 1500, C07F 1502

540145

A family of benzochlorins, a family of verdins, a family of porphyrin derivatives and metal complexes thereof are disclosed. The benzochlorins have the formula of FIG. 3 of the attached drawings; their metal complexes have the formula of FIG. 1. The verdins have the formulas of FIGS. 4 and 6 of the attached drawings; their metal complexes have the formulas of FIGS. 2 and 5. The porphyrin derivatives have the formula of FIG. 9 of the attached drawings; their metal complexes have the formula of FIG. 10. Solutions of the benzochlorins, verdins, porphyrin derivatives and metal complexes which are physiologically acceptable for intravenous administration are also disclosed, as are emulsions or suspensions of the solutions, and compositions which additionally include cyclodextrin, and wherein the molecules of the benzochlorin, verdin, porphyrin derivative or metal complex are encapsulated within the molecules of the cyclodextrin. The solvent for the solutions can be a product of the reaction of ethylene oxide with castor oil. A method for detecting and treating tumors in human and animal patients is also disclosed.

5354858, Oct 11, 1994

Jul 8, 1992

7/912079

Alan R. Morgan - Swanton OH
Steven H. Selman - Toledo OH

The University of Toledo - Toledo OH
Medical College of Ohio - Toledo OH

C07D48722

540145

Families of Diels Alder adducts and of metal complexes of Diels Alder adducts, which are useful as particularly active compounds for use in photodynamic therapy, are disclosed. The Diels Alder adducts and a preferred family of metal complexes have the structures of Formula 1, Formula 2, Formula 3 and Formula 4, below: ##STR1## where R1, R2, R3 and R4 can be the same or different, and each is methyl or ethyl, R5, R6 and R7 are ethyl, R8 is an alkyl group other than t-butyl having from one to four carbon atoms and M comprises a metal cation, e. g. , Sn or Zn, that is complexed with two of the nitrogens of the adduct. The use of the adducts and complexes in photodynamic therapy is also disclosed.

5563262, Oct 8, 1996

Oct 11, 1994

8/321387

Alan R. Morgan - Santa Barbara CA
Steven H. Selman - Toledo OH

University of Toledo - Toledo OH
Medical College of Ohio - Toledo OH

C07D48722, A61K 3166

540145

Families of Diels Alder adducts and of metal complexes of Diels Alder adducts, which are useful as particularly active compounds for use in photodynamic therapy, are disclosed. The Diels Alder adducts and a preferred family of metal complexes have the structures of Formulas 1, 2, 3 and 4, below: ##STR1## where R1, R2, R3 and R4 can be the same or different, and each is methyl, ethyl or an amino acid moiety which is a part of an amide produced by reaction between an amine function of a naturally occurring amino acid and a carbonyl function of the adduct, R5, R6 and R7 can be the same or different, and each is ethyl or an amino acid moiety which is a part of an amide produced by reaction between an amine function of a naturally occurring amino acid and a carbonyl function of the adduct, M comprises a metal cation, e. g. , Sn or Zn, that is complexed with two of the nitrogens of the adduct, and R8 is an alkyl group other than t-butyl having from one to four carbon atoms. The use of the adducts and complexes in PHD is also disclosed.

5514669, May 7, 1996

Sep 29, 1993

8/128792

Steven H. Selman - Toledo OH

Medical College of Ohio - Toledo OH

A61K 31555, A61K 31695

514 63

The present invention provides a method for diagnosing or treating prostatic tissue in a human or animal patient which comprises sensitizing the prostatic tissue with an effective amount of a photosensitive composition which accumulates in the prostatic tissue and exposing the sensitized tissue to a source of light energy for a predetermined time and intensity sufficient to cause cellular and/or tissue function of the sensitized prostatic tissue to diminish or cease.

5405369, Apr 11, 1995

Jan 25, 1994

8/187048

Steven H. Selman - Toledo OH
Kenneth A. Kropp - Toledo OH
Gregory D. Haselhuhn - Toledo OH

Medical College of Ohio - Toledo OH

A61B 1700

607 88

The present invention provides a method for treating a human or animal patient amenable an organ augmentation with gastro-intestinal tissue which is, or will be surgically transplanted into the patient's organ. The gastro-intestinal tissue is sensitized with an effective amount of a photosensitive composition which accumulates in the gastro-intestinal tissue. The sensitized tissue is exposed to a source of electromagnetic radiation energy for a predetermined time, wavelength and intensity sufficient to cause cellular and/or mucosal tissue function of the sensitized tissue to diminish or cease.